Skip to content

Pipeline

Pipeline and catalyst calendar

Where every compound stands and what is expected next. Dates are company guidance unless marked otherwise, and they often slip.

See the evidence maps: weight loss vs side effects, every trial arm, outcomes and timeline →

Pipeline map

Every obesity drug in Phase 2 or later, by how it works

From Phase 2 to approval. Rows are the hormones a drug acts on, columns are how far it has got.

29Programs shown
14Companies
8Available or tested as a pill
7Built on amylin
Mechanism

Phase 2

7 programs

Phase 3

14 programs

Filed

1 program

Approved

7 programs
GLP-1 onlySingle-hormone drugs, peptide or pill
CT-996Roche
NaperiglipronEli Lilly
Berobenatide (MET-097i)PfizerMonthly
Elecoglipron (AZD5004)AstraZeneca
AleniglipronStructure TherapeuticsPhase 3 starting
EcnoglutideSciwind Biosciences
WegovyNovo NordiskWegovy HD (7.2 mg)Novo NordiskWegovy pillNovo NordiskSaxendaNovo NordiskFoundayo (orforglipron)Eli Lilly
GLP-1 + GIPDual incretins, including GIP blockers
VK2735 oralViking TherapeuticsPhase 3 planned
MariTideAmgenMonthly, GIP blockedVK2735Viking Therapeutics
Enicepatide (CT-388)Roche
Zepbound (tirzepatide)Eli Lilly
GLP-1 + glucagonAdds energy burn and liver fat effects
PemvidutideAltimmune
SurvodutideBoehringer / ZealandPhase 3 complete
MazdutideInnovent / Eli LillyChina only
GLP-1 + GIP + glucagonTriple agonists
RetatrutideEli LillyPhase 3 complete
AmylinThe fullness hormone, alone
MET-233iPfizerMonthly
EloralintideEli LillyPetrelintideZealand / RochePhase 3 starting
CagrilintideNovo Nordisk
LenbelintideAstraZeneca
Amylin + GLP-1Combinations and single molecules
AmycretinNovo NordiskShot and pill
CagriSemaNovo NordiskFDA decision expected
Muscle and otherAntibodies that target muscle loss
BimagrumabEli LillyWith semaglutide
ApitegromabScholar RockWith tirzepatide
Phase 2Phase 3FiledApproved Injection PillTap a highlighted drug for its full profile

Status as of Oct 17, 2026, from company announcements and public pipeline trackers. Phase 1 programs are left out because most companies do not disclose them. Stages move often, so check the catalyst calendar below for what is next.

Sources for drugs without a full profile

Approved

Filed or Phase 3 complete

  • CagriSema Novo Nordisk
    Amylin + GLP-1 combination · Under FDA review
  • Retatrutide Eli Lilly
    GIP/GLP-1/glucagon triple agonist · Phase 3 complete
  • Survodutide Boehringer Ingelheim / Zealand
    GLP-1/glucagon dual agonist · Phase 3 complete

In development

  • MariTide Amgen
    GLP-1 agonist + GIP receptor blocker (antibody) · In Phase 3
  • Amycretin Novo Nordisk
    Amylin/GLP-1 unimolecular agonist · In Phase 3
  • Eloralintide Eli Lilly
    Amylin receptor agonist · In Phase 3
  • Petrelintide Zealand Pharma / Roche
    Amylin receptor agonist · Phase 3 starting
  • VK2735 Viking Therapeutics
    GIP/GLP-1 dual agonist · In Phase 3

Catalyst calendar

Upcoming decisions, filings and readouts

Q4 2026 FDA decision
FDA decision on CagriSema for obesity
Company guidance
Q4 2026 Trial start
Oral VK2735 Phase 3 program starts
Company guidance
H2 2026 Trial start
Petrelintide Phase 3 program starts
Company guidance
End 2026 Trial start
Phase 3 of eloralintide + tirzepatide combination starts
Company guidance
Q1 2027 Filing
Eli Lilly submits retatrutide to the FDA
Company guidance
By Feb 2027 FDA advisory
FDA advisory committee reviews GHK-Cu for compounding
FDA statement
2027 Readout
First MariTide Phase 3 (MARITIME) readouts
Trial estimate
2027 Readout
VANQUISH Phase 3 trials complete
Trial estimate
~2028 FDA decision
Earliest likely US approval of retatrutide (standard review)
Our estimate

Recent events

The last 12 months